Bayer Earnings Top Estimates on Crop Science, Soybean Gains


In its pharmaceutical division, Bayer continued to suffer from generic competition to Xarelto, with sales of the blockbuster blood thinner slumping by 40% in the quarter, as well as eye medicine Eylea. The company is counting on growth from cancer drug Nubeqa and kidney therapy Kerendia, as well as new launches, to return the unit to growth by 2027.



Source link

  • Related Posts

    Starmer Losing Fight to Stay in Power as Rebellion Spreads

    (Bloomberg) — Keir Starmer was facing growing pressure to step down as Britain’s prime minister after dozens of members of Parliament, including Cabinet allies, joined the calls for him to…

    ‘Final touches’ underway at FIFA World Cup venues in Vancouver, Toronto

    Hard hats and orange cones have been a frequent sight at B.C. Place for well over a year amid a flurry of construction. Hard hats and orange cones have been…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Priceline Promo Codes: 10% Off May 2026

    Priceline Promo Codes: 10% Off May 2026

    Six Military Aircraft With The Highest Service Ceilings In Service Today

    Six Military Aircraft With The Highest Service Ceilings In Service Today

    Devil May Cry Season 2 Review

    Devil May Cry Season 2 Review

    Canada Gazette – Part I, October 29, 2022, Vol. 156, No. 44

    Starmer Losing Fight to Stay in Power as Rebellion Spreads

    Starmer Losing Fight to Stay in Power as Rebellion Spreads

    Ontario auditor general to release report into government use of artificial intelligence

    Ontario auditor general to release report into government use of artificial intelligence